Suven Life Sciences has been granted a patent each by Europe, Japan and New Zealand for a drug used in the treatment of neuro-degenerative diseases.
The company said in a BSE filing today that it has been granted “one process patent from Europe, one process patent from Japan and one process patent from New Zealand corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with neurodegenerative diseases“.
The patents are valid till 2034, the company added.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Suven Life CEO Venkat Jasti said.
Suven Life Sciences shares were trading higher by 4.41 per cent at Rs 164.50 on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.